GNR-069 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 63 | Idiopathic thrombocytopenic purpura | 2 |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05492409 (ClinicalTrials.gov) | March 28, 2022 | 3/8/2022 | Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients | Extension Study of Long-term Safety and Immunogenicity of GNR-069 Patients With Idiopathic Thrombocytopenic Purpura Who Completed Phase 3 RMP-ITP-III Clinical Trial | Idiopathic Thrombocytopenic Purpura | Biological: GNR-069 | AO GENERIUM | NULL | Enrolling by invitation | 18 Years | 75 Years | All | 160 | Phase 3 | Russian Federation |
| 2 | NCT05220878 (ClinicalTrials.gov) | September 9, 2021 | 21/1/2022 | Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP | Multicenter Randomized Double-blind Comparative Study of Clinical Efficacy and Safety of GNR-069 (JSC GENERIUM, Russia) and Nplate (Amgen Europe BV, The Netherlands) in Patients With Idiopathic Thrombocytopenic Purpura | Idiopathic Thrombocytopenic Purpura | Biological: GNR-069;Biological: Nplate | AO GENERIUM | NULL | Recruiting | 18 Years | 75 Years | All | 160 | Phase 3 | Russian Federation |